Provenge News

erisian

http://www.zerocancer.org/site/News2?page=NewsArticle&id=11424

Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented

"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."

Let's hope so.

erisian

More info
"...PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death..."

Here are a couple of links on the subject:

Dendreon press release:
http://tinyurl.com/Provenge-PR

PDF of presentation on the IMPACT study given at ASCO-GU conference:
http://tinyurl.com/Provenge-pdf